Overview

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether weight gain will be significantly less in LY2140023 than aripiprazole in patients with schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Aripiprazole